Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.50 |
| ▸ | RAB9A | P51151 | 9/20 | 0.50 |
| ▸ | MAPT | P10636 | 9/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | STAT1 | P42224 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 7/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14926696 | 0.83 | NPC1 (0.62) | NPC1RAB9AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL14926679 | 0.81 | MAPT (0.60) | NPC1RAB9AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL13312943 | 0.81 | MAPT (0.60) | NPC1RAB9AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL14926692 | 0.81 | MAPT (0.60) | NPC1RAB9AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL18590721 | 0.81 | MAPT (0.60) | NPC1RAB9AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL11798432 | 0.78 | RAB9A (0.58) | NPC1RAB9AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL11798438 | 0.78 | RAB9A (0.58) | NPC1RAB9AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL10038795 | 0.78 | NPC1 (0.56) | NPC1RAB9AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL15677254 | 0.78 | NPC1 (0.56) | NPC1RAB9AMAPTMAPK1SMN1; SMN2 | |
| SCHEMBL9921385 | 0.77 | NOS1 (0.61) | NPC1RAB9AMAPTMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11980628-B2 | Prostate cancer treatment via synergistic inhibition of aryl hydrocarbon receptor (AhR) and SRC | CLARK ATLANTA UNIVERSITY, INC. (US) | 2024-05-14 | — | — | US | claimed |
| CN-107709546-B | Method for producing highly functional platelets | 国立大学法人京都大学 | 2022-04-22 | — | — | CN | claimed |
| US-20210393652-A1 | PROSTATE CANCER TREATMENT VIA SYNERGISTIC INHIBITION OF ARYL HYDROCARBON RECEPTOR (AHR) AND SRC | CLARK ATLANTA UNIVERSITY, INC. (US) | 2021-12-23 | — | — | US | claimed |
| US-10947504-B2 | Method for producing highly functional platelets | KYOTO UNIVERSITY (JP) | 2021-03-16 | — | — | US | claimed |
| EP-3312270-B1 | HIGH-PERFORMANCE PLATELET MANUFACTURING METHOD | UNIV KYOTO (JP) | 2020-09-30 | — | — | EP | claimed |
| US-20190048317-A1 | Method for Producing Highly Functional Platelets | KYOTO UNIVERSITY (JP) | 2019-02-14 | — | — | US | claimed |
| US-20180153910-A1 | PROSTATE CANCER TREATMENT VIA SYNERGISTIC INHIBITION OF ARYL HYDROCARBON RECEPTOR (AHR) AND SRC | CLARK ATLANTA UNIVERSITY, INC. | 2018-06-07 | — | — | US | claimed |
| EP-3312270-A1 | HIGH-PERFORMANCE PLATELET MANUFACTURING METHOD | Kyoto University (JP) | 2018-04-25 | — | — | EP | claimed |
| US-20240167034-A1 | METHODS AND COMPOSITIONS FOR REJUVENATING CNS GLIAL POPULATIONS BY SUPPRESION OF TRANSCRIPTION FACTORS | UNIVERSITY OF ROCHESTER | 2024-05-23 | — | — | US | disclosed |
| US-11980628-B2 | Prostate cancer treatment via synergistic inhibition of aryl hydrocarbon receptor (AhR) and SRC | CLARK ATLANTA UNIVERSITY, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4342982-A1 | METHOD FOR PRODUCING MULTINUCLEATED MEGAKARYOCYTE WITH ENHANCED PLATELET PRODUCTION CAPABILITY, METHOD FOR PRODUCING PLATELETS, METHOD FOR PRODUCING PLATELET PREPARATION, AND METHOD FOR PRODUCING BLOOD PREPARATION | Megakaryon Corporation (JP) | 2024-03-27 | — | — | EP | disclosed |
| US-20240052418-A1 | METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-02-15 | — | — | US | disclosed |
| CN-117500913-A | Method for producing multinucleated megakaryocyte having enhanced platelet production ability, method for producing platelets, method for producing platelet preparation, and method for producing blood preparation | 株式会社美加细胞 | 2024-02-02 | — | — | CN | disclosed |
| US-11814681-B2 | Method for predicting a subjects response to SLC modulator therapy | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-14 | — | — | US | disclosed |
| US-20130052160-A1 | COMPOUNDS AND USES THEREOF TO INDUCE AN IMMUNOGENIC CANCER CELL DEATH IN A SUBJECT | INSTITUT GUSTAVE ROUSSY (FR) | 2013-02-28 | — | — | US | disclosed |
| EP-2561088-A1 | COMPOUNDS AND USES THEREOF TO INDUCE AN IMMUNOGENIC CANCER CELL DEATH IN A SUBJECT | Institut Gustave Roussy (FR) | 2013-02-27 | — | — | EP | disclosed |
| WO-2012102937-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012007783-A1 | KITS AND METHODS FOR DETECTING THE ABILITY TO INDUCE AN IMMUNOGENIC CANCER CELL DEATH IN A SUBJECT | INSTITUT GUSTAVE ROUSSY (FR) | 2012-01-19 | — | — | WO | disclosed |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-07-22 | — | — | US | disclosed |
| WO-2010059401-A2 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | IRM LLC (BM) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240167034-A1 | METHODS AND COMPOSITIONS FOR REJUVENATING CNS GLIAL POPULATIONS BY SUPPRESION OF TRANSCRIPTION FACTORS | IKZF3, IKZF1, CXXC4 | NPC1 3427/4885RAB9A 4308/4885MAPT 3029/4885 |
| US-20180153910-A1 | PROSTATE CANCER TREATMENT VIA SYNERGISTIC INHIBITION OF ARYL HYDROCARBON RECEPTOR (AHR) AND SRC | AHR, AR, ARNT | NPC1 3443/4885RAB9A 3578/4885MAPT 3507/4885 |
| US-20210393652-A1 | PROSTATE CANCER TREATMENT VIA SYNERGISTIC INHIBITION OF ARYL HYDROCARBON RECEPTOR (AHR) AND SRC | AHR, AR, ARNT | NPC1 3443/4885RAB9A 3578/4885MAPT 3507/4885 |
| US-20100183564-A1 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS | CD47, HCLS1, CD74 | NPC1 1964/4885RAB9A 619/4885MAPT 4494/4885 |
| US-11980628-B2 | Prostate cancer treatment via synergistic inhibition of aryl hydrocarbon receptor (AhR) and SRC | AHR, AR, ARNT | NPC1 3443/4885RAB9A 3578/4885MAPT 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.